User Performance and System Accuracy Evaluations Using Glucose Adjustment

LifeScan

Status

Completed

Conditions

Type 1 Diabetes Mellitus

Treatments

Device: Blood Glucose Monitoring Systems.

Study type

Interventional

Funder types

Industry

Identifiers

NCT02374879

3128466

Details and patient eligibility

About

This is an open-label, non-randomised pilot study, to evaluate user performance and system accuracy in blood Glucose monitoring system with glucose adjustment. Twelve male and female volunteers aged 18-45, with a documented diagnosis of Type I diabetes for at least 12 will be enrolled in this study.

Enrollment

12 patients

Sex

All

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Summary of inclusion criteria.

Male and female volunteers aged 18-45, with a documented diagnosis of Type I diabetes for at least 12 months and treated with a basal bolus insulin regime, and deemed otherwise healthy as determined by medical history, physical examination, laboratory test values, vital signs and 12-lead ECGs at screening.
Non-smokers from at least 12 months before study start and for the duration of the study.
Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2.
Able to voluntarily provide written informed consent to participate in the study.
Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol, as confirmed during the informed consent process.
Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS).
The volunteer's primary care physician has confirmed within the last 12 months that there is nothing in their medical history that would preclude their enrolment into a clinical study.
User Performance Accuracy Testing Only: Self-Monitoring - Volunteer is currently performing unassisted self-monitoring of blood glucose.

Summary of exclusion criteria.

A severe hypoglycaemic reaction, defined as causing loss of consciousness and/or requiring outside assistance with oral or intravenous glucose or a glucagon injection, within 7 days of the study start date.
Female volunteers who are pregnant or lactating.
Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
Current or history of drug or alcohol abuse or a positive drugs of abuse or alcohol test at screening or check-in.
Participation in a clinical drug study during the 90 days prior to study start.
Any clinically significant illness within 30 days prior to study start.
Donation of blood or blood products within 30 days prior to study start, or at any time during the study, except as required by this protocol.
Weekly alcohol intake exceeding the equivalent of 14 units per week for females or 21 units per week for males.
Consumption of alcoholic beverages within 48 hours prior to check-in.
Volunteers with a substantial change in eating habits within 30 days prior to study start or volunteers who cannot comply with the standardised meals proposed for use in the study.
Prior experience with the BGMSs used for the study.
Volunteers who are currently working for, have previously worked for, or have an immediate family member working for a company that manufactures or markets blood glucose monitoring products.
Volunteers who have laboratory training or experience (medical technologist, laboratory technician, laboratory assistant etc).
Volunteers who, in the opinion of the Investigator, are unsuitable for participation in the study.